| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/17/2002 | US20020006927 Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| 01/17/2002 | US20020006926 Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| 01/17/2002 | US20020006921 Dopaminergic agent |
| 01/17/2002 | US20020006917 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 01/17/2002 | US20020006908 Anticonvulsant derivatives useful in treating schizophrenia |
| 01/17/2002 | US20020006905 Use of botulinum toxins for treating various disorders and conditions and associated pain |
| 01/17/2002 | US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 01/17/2002 | US20020006400 Recombinant human CLN2 protein and methods of its production and use |
| 01/17/2002 | DE10031651A1 Extrakte aus Sophora-Arten, Verfahren zu ihrer Herstellung und Verwendung Extracts of Sophora species, processes for their preparation and use |
| 01/17/2002 | DE10031650A1 Verwendung von Extrakten aus Sophora flavescens oder Sophora subprostrata zur Prophylaxe und Therapie von Krankheitszuständen, die durch einen Mangel an Östrogenen oder durch andere hormonelle Dysregulationen verursacht werden The use of extracts from Sophora flavescens or Sophora subprostrata for the prophylaxis and treatment of pathological conditions caused by estrogen deficiency or by other hormonal dysregulation |
| 01/17/2002 | DE10031390A1 Pyrimidinderivate und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie Pyrimidine derivatives and their use for the prophylaxis and therapy of cerebral ischemia |
| 01/17/2002 | DE10005302A1 Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/17/2002 | CA2416199A1 Adenosine compound and pharmaceutical composition containing the same |
| 01/17/2002 | CA2415919A1 Reagents and methods for identification of binding agents |
| 01/17/2002 | CA2415815A1 Tetrahydrobenzothiazole analogues as neuroprotective agents |
| 01/17/2002 | CA2415808A1 Transporters and ion channels |
| 01/17/2002 | CA2415179A1 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 01/17/2002 | CA2415127A1 Down syndrome critical region 1-like 1 proteins |
| 01/17/2002 | CA2415084A1 Olfactory neuron cultures and method of making and using the same |
| 01/17/2002 | CA2414938A1 Combinations of ssri and estrogenic agents |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414219A1 Lipid metabolism molecules |
| 01/17/2002 | CA2414198A1 Melanin concentrating hormone receptor ligands |
| 01/16/2002 | EP1172378A1 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| 01/16/2002 | EP1172376A1 Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis |
| 01/16/2002 | EP1172364A1 A process for the preparation of 2-phenyl-imidazo[1,2-A]pyridine-3-acetamides |
| 01/16/2002 | EP1172360A1 Neurotrophin potentiators |
| 01/16/2002 | EP1172113A1 Remedies for autonomic neuropathy |
| 01/16/2002 | EP1172111A1 Pharmaceutical composition with adhesion molecule expression regulating activity |
| 01/16/2002 | EP1172106A2 Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists |
| 01/16/2002 | EP1171626A1 50 human secreted proteins |
| 01/16/2002 | EP1171596A1 Synthetic transmembrane components |
| 01/16/2002 | EP1171590A1 50 human secreted proteins |
| 01/16/2002 | EP1171589A1 A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof |
| 01/16/2002 | EP1171579A1 Human tumor necrosis factor receptor tr9 |
| 01/16/2002 | EP1171573A1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 01/16/2002 | EP1171462A2 49 human secreted proteins |
| 01/16/2002 | EP1171458A1 50 human secreted proteins |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171456A1 50 human secreted proteins |
| 01/16/2002 | EP1171444A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines |
| 01/16/2002 | EP1171442A1 Xanthine derivatives and analogs as cell signalling inhibitors |
| 01/16/2002 | EP1171441A1 Morphinoid compounds |
| 01/16/2002 | EP1171439A1 Azaindole derivatives for the treatment of depression |
| 01/16/2002 | EP1171434A1 Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression |
| 01/16/2002 | EP1171431A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171425A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins |
| 01/16/2002 | EP1171424A1 Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 01/16/2002 | EP1171423A1 Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands |
| 01/16/2002 | EP1171419A1 Biphenyl derivatives as antagonists of the neurokinine-1 receptor |
| 01/16/2002 | EP1171416A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
| 01/16/2002 | EP1171414A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171160A1 Method and means for treating post-polio syndrome |
| 01/16/2002 | EP1171159A2 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) |
| 01/16/2002 | EP1171154A2 Uses of mammalian ox2 protein and related reagents |
| 01/16/2002 | EP1171153A2 Novel medical use of alpha-1-acidic glycoprotein (aag) or orosomucoid |
| 01/16/2002 | EP1171147A1 Modulation of excitable tissue function by peripherally administered erythropoietin |
| 01/16/2002 | EP1171146A1 Pharmaceutical compositions containing selegiline and ginkgo biloba extract useful for dementia |
| 01/16/2002 | EP1171142A1 Inflammatory mediation obtained from atractylodes lancea |
| 01/16/2002 | EP1171141A1 MEDICAMENT FOR INHIBITING NF-kB |
| 01/16/2002 | EP1171139A2 Compositions containing rubidium and in particular rubidium chloride as an antimanic agent and stabilizer for mood swings |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171133A2 R-hydroxynefazodone |
| 01/16/2002 | EP1171132A1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
| 01/16/2002 | EP1171131A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 01/16/2002 | EP1171130A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 01/16/2002 | EP1171129A1 Use of glucosylceramide synthesis inhibitors in therapy |
| 01/16/2002 | EP1171128A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 01/16/2002 | EP1171125A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171123A1 Method for treating neurodegeneration |
| 01/16/2002 | EP1171120A1 Methods for alleviating discomfort of a hot flash and compositions therefor |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1171113A1 Compounds useful as phosphotyrosine mimics |
| 01/16/2002 | EP1171112A2 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients |
| 01/16/2002 | EP1171101A1 Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix |
| 01/16/2002 | EP1171099A1 Composition containing opioid antagonists and spray dispenser |
| 01/16/2002 | EP1007067B1 Pharmaceutical compositions containing parthenium integrifolium or parts thereof or an extract or component thereof, the use of such plant material for preparing certain medicines, and a method of preparing an extract of parthenium integrifolium |
| 01/16/2002 | EP0883619B1 Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type |
| 01/16/2002 | CN1331801A Kidney disease detection and treatment |
| 01/16/2002 | CN1331698A Brain cell or nerve cell-protective agents comprising ginsenoside Rb1 |
| 01/16/2002 | CN1331692A Benzisozazoles and phenones as alpha antagonist |
| 01/16/2002 | CN1331688A Aminopyrazole derivatives |
| 01/16/2002 | CN1331685A Method for preph. of citalopram |
| 01/16/2002 | CN1331684A Sulphoneylxazolamines as therapeutic active ingredients |
| 01/16/2002 | CN1331683A 2-phenylbenzimidazoles and 2-phenylindoles, and prodn. and use thereof |
| 01/16/2002 | CN1331682A Substituted 2-phenylbenzimidazoles, prodn. thereof and their use |
| 01/16/2002 | CN1331679A 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands |
| 01/16/2002 | CN1331596A Controlled release galantamine composition |
| 01/16/2002 | CN1331595A Triazine compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| 01/16/2002 | CN1331594A Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| 01/16/2002 | CN1331586A Transparent transdermal nicotine delivery devices |
| 01/16/2002 | CN1331576A Methods and transdermal compsns. for pain relief |
| 01/16/2002 | CN1331217A Polypeptide-human EHD protein 9.57 and polynucleotide for coding it |
| 01/16/2002 | CN1331083A Memory-improving peptides and their application |
| 01/16/2002 | CN1330950A Chinese medicine for optimally taking care of brain health |
| 01/16/2002 | CN1330944A Tea for giving up smoking |
| 01/16/2002 | CN1330935A Drug-dropping Chinese patent medicine for improving immunity of human body itself |
| 01/16/2002 | CN1077890C 4-aminoethyoxy-indolone derivatives as dopamine D2 agonists |
| 01/16/2002 | CN1077889C Piperazine derivatives and their use as 5-HT1A antagonists |
| 01/16/2002 | CN1077799C prevention of retinal injury and degeneration by specfic factors |